Αποτελέσματα Αναζήτησης
8 Οκτ 2024 · Abstract. Factor Xa inhibitors (FXaI) are increasingly used for anticoagulation therapy, yet their association with intracranial hemorrhage poses a significant challenge. Although andexanet alfa (AA) and four-factor prothrombin complex concentrate (4F-PCC) have shown promise in reversing FXaI effects, their comparative efficacy and safety ...
Two agents that are used for DOAC reversal, specifically rivaroxaban and apixaban, are 4-factor prothrombin complex concentrate (4F-PCC) and andexanet alfa (AA).
9 Αυγ 2013 · Prothrombin complex concentrate (PCC) provides an alternative to fresh frozen plasma for reversal of VKA-induced coagulopathy (Table). Originally developed as a source of factor IX for treatment of patients with hemophilia B, 3-factor PCC contains factors II, IX, and X but little or no factor VII.
24 Ιαν 2022 · PCC4 is more effective than PCC3 in meeting specific predefined INR goals and has similar safety profiles in patients requiring emergent reversal of the anticoagulant effects of warfarin. Peer Review reports. Background.
28 Οκτ 2024 · Multiple agents exist for the reversal of oral Factor Xa inhibitor (FXa) associated bleeding, including Coagulation FXa Recombinant, Inactivated zhzo (andexanet alfa) and 4-factor prothrombin complex concentrate (4F-PCC). While classified as a 3F-PCC product, Profilnine contains up to 35 IU of Factor VII (per 100 IU of Factor IX) in addition to therapeutic levels of Factors II, IX, and X, and ...
30 Οκτ 2024 · Despite the heterogeneity of study designs, the use of 4F-PCCs for intracerebral hemorrhage in anticoagulated patients is reported with favorable outcomes in terms of INR reversal for VKA-treated patients as well as 30-day mortality and thromboembolic events in oral anticoagulated patients. 72–80 A propensity score–weighted analysis of ...
5 Ιουλ 2024 · Background: There is currently a lack of evidence for the comparative effectiveness of Andexanet alpha and four-factor prothrombin complex concentrate (4F-PCC) in anticoagulation reversal of direct oral anticoagulants (DOACs).
